Background:TMD – is the second most common cause of musculoskeletal pain and disability and the most common cause of orofacial pain. It is of multifactorial origin and associated with various risk factors. Treatment includes physical, pharmacological, surgical, and behavioral therapy. Various pharmacological agents were used in the management of temporomandibular disorders. Tricyclic antidepressants are increasingly used due to their chronic pain-relieving potential in lower doses. Methodology and Results:A retrospective analysis of the management of temporomandibular joint disorders with antidepressants was analyzed (N - 42 cases). Clinical parameters such as VAS and mouth opening were evaluated. Descriptive statistics were given and paired t-test was used to determine the mean and standard deviation of pre and post-treatment VAS and mouth opening. There is a significant reduction of pain and improvement in mouth opening evident with the use of antidepressants Conclusion:This retrospective study analyses the exclusive use of Tricyclic antidepressants in temporomandibular disorders.TCA can safely be used as a primary therapeutic modality in TMD to improve quality of life.